Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 23 |
| Active Pipeline (Recruiting Now) | 21 (10) |
| Completed vs Stopped Early | 0 / 1 (4.3%) |
| Median Closed Actual Enrollment | 91 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT06652438 | Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML | Phase III | RECRUITING |
| NCT07223814 | Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Mye | Phase III | RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the Stichting Hemato-Oncologie voor Volwassenen Nederland Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.